Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
Authors:
- Rafiye ÇiftçilerRÇRafiye Çiftçiler
- Hakan GökerHGHakan Göker
- Haluk DemiroğluHDHaluk Demiroğlu
- Elifcan AladağEAElifcan Aladağ
- Salih AksuSASalih Aksu
- İbrahim Calalettin HaznedaroğluİHİbrahim Calalettin Haznedaroğlu
- Nilgün SayınalpNSNilgün Sayınalp
- Osman ÖzcebeOÖOsman Özcebe
- Fatma TekinFTFatma Tekin
- Yahya BüyükaşıkYBYahya Büyükaşık
Open Access
- 3 May 2019
- journal article
- research article
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 36 (2) , 88-96
Abstract
Objective: Allogeneic hematopoietic stem cell transplantation (HSCT) is an effective treatment modality for a variety of malignant and non-malignant hematologic disorders. Myeloablative conditioning (MAC) and reduced-intensity conditioning (RIC) regimens could have different clinical outcomes. This purpose of this study was to assess the long-term outcome of MAC versus RIC regimens in patients with acute myeloid leukemia (AML) undergoing allogeneic HSCT. Materials and Methods: We retrospectively compared long-term outcomes with MAC and RIC regimens in patients with AML who underwent allo-HSCT at our tertiary transplantation center. Results: We analyzed survival outcomes after MAC-HSCT versus RIC-HSCT among 107 adult patients with AML diagnosed from 2001 through 2017. Of those, 44 patients underwent a MAC regimen, whereas 63 patients received a RIC regimen. The median follow-up time was 37 months (range: 6-210) for the entire group. The 3-year overall survival (OS) for RIC and MAC patients was 67% and 60%, respectively (p> 0.05). The 3-year progression-free survival (PFS) for RIC and MAC patients was 88% and 77%. In multivariate analysis, the type of conditioning regimen (RIC vs. MAC) did not influence PFS (p=0.24). Acute graft-versus-host disease (GVHD) was seen in five of the RIC patients and 9 of the MAC patients. Chronic GVHD was seen in 16 of the RIC patients and 6 of the MAC patients. There was no significant difference between the two groups in terms of acute GVHD (p=0.089), but there was a significant difference between the two groups in terms of chronic GVHD (p=0.03). Conclusion: This retrospective analysis confirmed that MAC and RIC regimens had a consistently equivalent rate of OS and PFS in AML patients who underwent allo-HSCT. The choice of MAC versus RIC conditioning regimen might be decided on the basis of patient and disease characteristics.Keywords
This publication has 28 references indexed in Scilit:
- Indications and outcomes of reduced-toxicity hematopoietic stem cell transplantation in adult patients with hematological malignanciesInternational Journal of Hematology, 2013
- Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trialThe Lancet Oncology, 2012
- The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approachNature Reviews Clinical Oncology, 2012
- Reduced intensity versus myeloablative allogeneic stem cell transplantation for the treatment of acute myeloid leukemia, myelodysplastic syndrome and acute lymphoid leukemiaCurrent Opinion in Oncology, 2011
- Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for acute myelogenous leukemiaJournal of Hematology & Oncology, 2010
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999
- Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.1999
- Intensifying induction therapy in acute myeloid leukemia: has a new standard of care emerged?1997
- Marrow Transplantation for Acute Nonlymphocytic Leukemia after Treatment with Busulfan and CyclophosphamideNew England Journal of Medicine, 1983